Phase 2b Study of GSK4532990 in Adults With NASH

Summary

The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

Timeline

Start

2023-01-02

Primary completion

2026-01-31

Completion

2026-09-23

Drugs

Indications